Bausch + Lomb Corporation
BLCOHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeBausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and. Valued at $5.80B, BLCO is a mid-cap name in its sector. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Market Cap
$5.80B
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
15.20
EPS (TTM)
$-0.60
EPS (Fwd)
$1.07
ROE
-3.3%
ROA
1.4%
Cash
$268.0M
Total Debt
$5.07B
Free CF
$238.5M
52W Change
17.0%
Annual Financials
Cash vs Debt
The company holds $268.0M in cash, though total debt stands at $5.07B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $238.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -3.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.4% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $3.77B (2022) to $5.10B (2025), reflecting a 35% increase over the period.
The relatively low beta of 0.56 suggests BLCO is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BLCO.